Clonal hematopoiesis is a condition in which a single blood-forming stem cell in bone marrow acquires a genetic mutation and then produces a disproportionately large share of your blood cells. It becomes strikingly common with age and is now recognized as an independent risk factor for cardiovascular disease, certain blood cancers, and a growing list of other conditions tied to chronic inflammation.1PubMed Central. Clonal hematopoiesis in human aging and disease The term you may encounter most often is CHIP, short for clonal hematopoiesis of indeterminate potential, which specifically refers to people who carry these mutations without any signs of a blood cancer or abnormal blood counts.2PubMed Central. Current Understanding of CHIP’s Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature What makes clonal hematopoiesis so interesting, and unsettling, is that its biggest health consequences happen outside the blood system entirely.
How a Single Mutant Stem Cell Takes Over
Your bone marrow contains a pool of hematopoietic stem cells that continuously divide and differentiate into every type of blood cell. Over a lifetime, these stem cells accumulate random mutations with each division. Most mutations do nothing useful for the cell. Occasionally, though, a mutation lands in a gene that gives the affected stem cell a subtle growth or survival advantage over its neighbors. That cell divides a little faster or resists signals that would normally keep its numbers in check. Over years or decades, the descendants of that one cell, its “clone,” gradually come to represent a larger and larger fraction of total blood production.
Recent modeling work has framed this as an ecological competition: clones with different fitness levels emerge at random times and compete for limited space in the stem cell pool. A clone with a modest advantage will expand steadily in a young person’s marrow, but as more mutant clones accumulate with age, the average fitness of the whole pool rises. That can actually slow down or even reverse the growth of clones with only a small edge, because they are now competing against fitter neighbors rather than normal cells.3PubMed Central. The Evolution of Polyclonal Competition in Aging Hematopoiesis This dynamic explains something researchers have puzzled over: why some clones expand relentlessly while others plateau or even shrink with time.
An additional twist is that mutant stem cells don’t just help themselves directly. Their mature offspring, particularly immune cells like macrophages, can reshape the bone marrow environment in ways that hurt normal stem cells while reinforcing the mutant ones. Inflammatory signals released by mutant immune cells create feedback loops that progressively tilt the playing field.4PubMed Central. Clonal hematopoiesis driver mutations: molecular mechanisms and clinical implications – inclusive fitness of pre-leukemic hematopoietic stem and progenitor cells through pro-inflammatory features of their progeny This is why clonal hematopoiesis is not simply a passive byproduct of aging but an active process that reshapes the immune system from within.
The Most Common Mutations
Not every gene mutation drives clonal hematopoiesis. The landscape is dominated by a handful of genes, and which ones matter depends heavily on context. In otherwise healthy older adults, the two most frequently mutated genes are DNMT3A and TET2, which together account for more than 70% of age-related clonal hematopoiesis cases.5Blood Advances. Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory response Both genes are involved in controlling DNA methylation, an epigenetic switch that turns genes on or off. Interestingly, they work in opposite directions: DNMT3A adds methyl groups to silence genes, while TET2 removes them to activate genes. Despite those opposing roles, mutations in either gene converge on a similar outcome: the mutant stem cell gains a self-renewal advantage, and its immune-cell descendants tend to be more inflammatory. ASXL1 and JAK2 round out the most commonly implicated genes in age-related CHIP.2PubMed Central. Current Understanding of CHIP’s Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature
The picture changes dramatically in people who have undergone chemotherapy or radiation. DNA-damaging treatments create an environment that selects for a different set of mutations, particularly in genes that help cells cope with DNA damage: TP53, PPM1D, ATM, and CHEK2. Clones carrying these mutations expand much faster during and after treatment than typical DNMT3A or TET2 clones do.6Leukemia. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer PPM1D mutations, for example, were found in roughly one in five patients with therapy-related leukemia or pre-leukemic blood disorders and were strongly linked to platinum-based chemotherapy exposure.7PubMed Central. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy The practical takeaway is that the mutation profile matters: age-related CHIP and therapy-related CHIP often involve different genes, carry different risks, and may eventually require different monitoring strategies.
Who Gets It and When
Clonal hematopoiesis is vanishingly rare in young adults and becomes extremely common in old age. Using standard sequencing that detects mutations present in at least 2% of blood cells, earlier landmark studies found CHIP in roughly 10% of people over 65. With more sensitive sequencing technologies that can pick up smaller clones, the numbers climb steeply. A study of people aged 90 and older found a significantly higher incidence of clonal hematopoiesis than in those aged 60 to 89, with certain mutations like TET2 and ASXL1 being especially common in the oldest group.8PubMed Central. The impact of age and number of mutations on the size of clonal hematopoiesis That study also raised an intriguing possibility: some forms of clonal hematopoiesis might not be harmful and could even be associated with longevity, though this remains speculative.
Beyond age, environmental exposures play a role. Smoking has a small but measurable association with CHIP. A meta-analysis across several cohorts found that every ten pack-years of smoking corresponded to about a 3% increase in the odds of carrying a CHIP mutation.9Blood. Association of clonal hematopoiesis with chronic obstructive pulmonary disease That is a modest effect compared to age itself, but it adds to the pile of reasons smoking is harmful to the vascular system.
The Cardiovascular Connection
This is where clonal hematopoiesis landed on the radar of cardiologists and reshaped the field’s thinking about heart disease risk. A landmark study published in the New England Journal of Medicine showed that people carrying CHIP mutations had roughly double the risk of coronary heart disease compared to non-carriers. In cohorts focused on early-onset heart attacks, meaning younger people, the risk was even more dramatic: a fourfold increase.10PubMed Central. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease Mutations in DNMT3A, TET2, ASXL1, and JAK2 were each independently linked to coronary disease, and carriers showed more coronary artery calcification, a physical sign of plaque buildup.
Heart failure tells a similarly concerning story. In patients who already had heart failure with reduced pumping function, those carrying DNMT3A or TET2 mutations experienced significantly faster disease progression. The hazard for heart-failure-related hospitalization or death was roughly three to four and a half times higher in mutation carriers, depending on the gene.11PubMed. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction This held true regardless of whether the heart failure had been caused by a prior heart attack or by some other process.12PubMed Central. Importance of clonal hematopoiesis in heart failure
Stroke risk is elevated as well, though the effect sizes are smaller than for coronary disease. In a large analysis, CHIP was associated with about a 14% increase in overall stroke risk after adjusting for age, sex, and race, with stronger links to hemorrhagic stroke and small vessel disease subtypes.13PubMed Central. Clonal hematopoiesis is associated with higher risk of stroke Gene-specific analyses have pointed to TET2 as a particularly strong driver of ischemic stroke risk and poor functional recovery afterward.14PubMed Central. Multi-Cohort Analysis Reveals Genetic Predispositions to Clonal Hematopoiesis as Mutation-Specific Risk Factors for Stroke A prospective study of first-ever stroke patients found that CHIP carriers were more likely to have a recurrent stroke within three months, but only if they also had elevated inflammation markers at baseline. In patients without that heightened inflammation, CHIP alone did not predict recurrence.15PubMed Central. Somatic mutation contributing to clonal haematopoiesis is a risk factor of recurrent stroke in first-ever acute ischaemic stroke: a prospective cohort study This finding neatly illustrates a recurring theme: clonal hematopoiesis seems to do most of its damage through inflammation, and the clinical consequences tend to be worst when inflammation is already running high.
Why Inflammation Is the Central Thread
The mechanism linking mutant blood cells to heart disease, stroke, and other conditions comes down to the immune system behaving badly. The best-studied pathway involves TET2-deficient macrophages, the immune cells that patrol artery walls and other tissues. When TET2 is lost, these macrophages ramp up activity of an inflammatory complex called the NLRP3 inflammasome, which triggers the release of a potent inflammatory signal called IL-1β.16PubMed Central. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice In mouse models, this accelerated plaque buildup in arteries. In the heart, TET2-deficient macrophages and the IL-1β and IL-6 they release can disrupt calcium handling in heart muscle cells, which may explain the link to atrial fibrillation.17PubMed Central. Clonal Hematopoiesis of Indeterminate Potential With Loss of Tet2 Enhances Risk for Atrial Fibrillation Through Nlrp3 Inflammasome Activation
More detailed work has uncovered how TET2 loss and high cholesterol work together to supercharge this inflammasome activation. In both mouse and human macrophages, TET2 deficiency combined with cholesterol loading increased the activity of a signaling enzyme called JNK1, which in turn activated the NLRP3 inflammasome through a specific molecular switch. Importantly, blocking this switch in human TET2-deficient macrophages reversed the excess inflammasome activity.18PubMed Central. BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis This synergy between clonal hematopoiesis and traditional cardiovascular risk factors like high cholesterol is a key reason researchers believe the condition does not operate in isolation. It amplifies existing risks rather than creating disease from nothing.
Blood Cancer Risk in Perspective
Given that clonal hematopoiesis involves mutations in cancer-related genes, the natural concern is leukemia. CHIP does increase the risk of developing acute myeloid leukemia and related blood cancers, but the absolute risk for any individual remains low. A study that tracked people over time found that those with clonal mutations detectable at a variant allele frequency of 2% or higher had about a fivefold increase in the odds of developing AML compared to people without detectable mutations.19PubMed Central. Clonal hematopoiesis and risk of acute myeloid leukemia A fivefold relative increase sounds alarming, but acute myeloid leukemia is rare to begin with. The vast majority of people with CHIP will never develop a blood cancer. The cardiovascular consequences are far more likely to affect them first.
Clone size matters here. Larger clones, meaning the mutation is present in a bigger share of blood cells, carry higher risk both for blood cancer and for cardiovascular events. The formal threshold for defining CHIP is a variant allele frequency of 2%, but smaller clones detected by more sensitive sequencing also appear to carry some prognostic information.20PubMed Central. Error-corrected ultradeep next-generation sequencing for detection of clonal haematopoiesis and haematological neoplasms – sensitivity, specificity and accuracy Researchers are now investigating whether tracking clone growth over time might help identify the small minority of people whose clones are on a trajectory toward cancer.
Kidney Disease and Infections
The inflammatory effects of clonal hematopoiesis extend beyond the heart and brain. Animal studies have shown that CHIP mutations can drive kidney inflammation and scarring, and epidemiological data from humans support a connection. In an East Asian cohort of patients with chronic kidney disease, those with CHIP had roughly double the risk of progressing to kidney failure after adjusting for other risk factors. This finding was replicated in UK Biobank data, where CHIP carriers also had about twice the risk of kidney failure over a roughly 13-year follow-up.21PubMed Central. Clonal Hematopoiesis of Indeterminate Potential and Kidney Failure in CKD An East Asian Cohort Study That said, the evidence is not uniformly positive. A study looking specifically at diabetic kidney disease found no significant association between CHIP and the development or worsening of kidney problems in people with diabetes.22Kidney International Reports. Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study Whether CHIP’s kidney effects are limited to certain types of kidney disease or only matter above certain clone sizes remains an open question.23PubMed Central. Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease
Infectious disease is another emerging area of concern. In a study of over 500 people with COVID-19, those with clonal hematopoiesis had roughly 85% higher odds of severe outcomes. The same research group found that among cancer patients, CHIP was associated with double the risk of Clostridium difficile infection and a significantly increased risk of infections caused by Streptococcus and Enterococcus bacteria.24Nature Communications. Clonal hematopoiesis is associated with risk of severe Covid-19 The proposed explanation fits the broader pattern: mutant immune cells that are stuck in a pro-inflammatory mode may be less effective at actually clearing infections, even as they drive tissue damage.
Not All Clonal Hematopoiesis Is Equally Dangerous
One of the most important practical points is that CHIP is not a single-risk condition. A scoring system for clonal hematopoiesis risk, developed using data from older adults, found dramatic differences in outcomes depending on mutation type, clone size, and number of mutations. People categorized as low-risk showed no statistically significant increase in death over about seven years of follow-up. Intermediate risk was similarly modest. But the high-risk group, defined by factors like larger clone size, multiple mutations, or high-risk gene involvement, had two and a half times the mortality rate of people without clonal hematopoiesis.25PubMed Central. Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults This is reassuring for the majority of CHIP carriers, who fall into lower-risk categories, but it underscores the need for better risk stratification tools.
Gene identity matters for risk as well. TET2 and JAK2 mutations appear to have the most clearly causal relationship with accelerated atherosclerosis.26PubMed Central. Managing Cardiovascular Risk in Clonal Hematopoiesis of Indeterminate Potential: JACC: CardioOncology Short-Form Primer DNMT3A mutations, while the most common overall, have a more complex risk profile. And in the cancer-treatment setting, the DNA damage response mutations like TP53 and PPM1D carry their own distinct concerns, including a higher likelihood of progression to therapy-related blood cancers.
Clonal Hematopoiesis and Cancer Treatment Outcomes
Beyond the well-established link to therapy-related blood cancers, researchers are now asking whether clonal hematopoiesis affects how well patients respond to treatment for solid tumors. The early evidence is mixed but concerning. In patients with head and neck cancers receiving immunotherapy, PPM1D mutations in the blood were correlated with shorter time to disease progression and shorter overall survival.27Journal of Clinical Oncology. Clonal hematopoiesis in head and neck carcinomas receiving immunotherapy In melanoma patients on immune checkpoint inhibitors, those who had both clonal hematopoiesis and a BRAF mutation in their tumor had significantly worse progression-free survival compared to patients without either.28Blood. Impact of clonal hematopoiesis and BRAF mutation status on clinical outcomes in melanoma patients treated with immune checkpoint inhibitors These are preliminary findings from relatively small studies, and the interactions between CHIP, tumor biology, and immunotherapy are almost certainly more complicated than a simple “CHIP bad” narrative. But the pattern is worth watching, especially for oncologists weighing treatment strategies in patients known to carry CHIP mutations.
What Can Be Done About It
Right now, there is no approved treatment specifically for clonal hematopoiesis. You cannot take a pill to eliminate a mutant clone. But the inflammatory mechanism offers a clear therapeutic target, and several strategies are being explored. The most compelling early signal came from a re-analysis of the CANTOS trial, which tested an IL-1β-blocking antibody in heart disease patients. Exploratory findings suggested that patients with TET2 CHIP mutations may have gotten an outsized benefit from the drug, though this observation remains hypothesis-generating and needs to be confirmed in trials specifically designed to test it.29PubMed Central. Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease: Gene-Specific Mechanisms and Therapeutic Implications
Current clinical trials are evaluating inflammasome blockers and IL-1-pathway inhibitors in patients selected for CHIP, as well as larger trials testing IL-6-targeted drugs for people with residual inflammatory cardiovascular risk, a category that overlaps heavily with CHIP carriers. In the meantime, the practical clinical approach centers on aggressive management of conventional cardiovascular risk factors. Because CHIP amplifies the harm caused by high cholesterol, high blood pressure, and smoking, controlling those standard risks becomes even more important if you carry a CHIP mutation. The mutation type and clone size can help guide how aggressively doctors push cardioprotective measures like statin therapy.26PubMed Central. Managing Cardiovascular Risk in Clonal Hematopoiesis of Indeterminate Potential: JACC: CardioOncology Short-Form Primer
The Incidental Discovery Problem
One of the awkward realities of modern genomic testing is that CHIP mutations are increasingly discovered by accident. If you get genetic testing for a cancer diagnosis, or participate in a research study, or undergo broad-panel screening for another reason entirely, a CHIP mutation might show up in the results. For most people, this information creates more anxiety than actionable medical guidance. There are no established screening guidelines recommending that healthy people get tested for CHIP. The genetics community is still grappling with the ethical questions around returning these results to patients: how much do you tell someone about a risk factor they cannot yet treat, and what psychological and insurance consequences might follow?
For cancer patients, the situation is slightly more concrete. If someone undergoing chemotherapy has their blood sequenced and a TP53 or PPM1D clone is found, that information could influence monitoring decisions for therapy-related blood cancers. But for the average older adult who learns they have a small DNMT3A clone, the main action item is the same advice they were already getting: manage your blood pressure, cholesterol, and other cardiac risk factors diligently. The field is moving rapidly, though. Within the next several years, dedicated CHIP clinics and gene-specific management pathways are likely to become more common, turning what is now an incidental curiosity into a routine part of cardiovascular risk assessment.